Vancomycin
- Generic Name
- Vancomycin
- Brand Names
- Firvanq, Vancocin
- Drug Type
- Small Molecule
- Chemical Formula
- C66H75Cl2N9O24
- CAS Number
- 1404-90-6
- Unique Ingredient Identifier
- 6Q205EH1VU
- Background
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
- Indication
Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associated diarrhea and for enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
- Associated Conditions
- Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
- Associated Therapies
- -
Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 110
- Registration Number
- NCT02463747
- Locations
- 🇮🇱
Tel-Aviv Sourasky Medicak center / BMT Unit, Tel-Aviv, Israel
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 100
- Registration Number
- NCT02443064
- Locations
- 🇨🇳
Yong-Hong Xiao, Hangzhou, Zhejiang, China
Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- University of Tennessee
- Target Recruit Count
- 11
- Registration Number
- NCT02400112
- Locations
- 🇺🇸
Erlanger Health System, Chattanooga, Tennessee, United States
A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 86
- Registration Number
- NCT02384200
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Phoenix, Arizona, United States
🇺🇸UCSD Medical Center, San Diego, California, United States
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 1037
- Registration Number
- NCT02374853
Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT02355938
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
The Role of the Microbiota in the Systemic Immune Response
- Conditions
- Interventions
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- W.J. Wiersinga, MD, PhD
- Target Recruit Count
- 12
- Registration Number
- NCT02340182
- Locations
- 🇳🇱
Academisch Medisch Centrum, Amsterdam, Noord-Holland, Netherlands
Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Spectrum Health Hospitals
- Target Recruit Count
- 700
- Registration Number
- NCT02299882
- Locations
- 🇺🇸
Spectrum Health Hospitals, Grand Rapids, Michigan, United States
Prevention of Infections in Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 3000
- Registration Number
- NCT02285140
- Locations
- 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦Jewish Hospital, Montréal, Quebec, Canada
Topical Vancomycin for Neurosurgery Wound Prophylaxis
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1103
- Registration Number
- NCT02284126
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.